ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: SA-PO866

Relationship between Bone Sialoprotein and Vascular Calcification in Maintenance Hemodialysis Patients

Session Information

  • Vascular Calcification
    November 04, 2017 | Location: Hall H, Morial Convention Center
    Abstract Time: 10:00 AM - 10:00 AM

Category: Mineral Disease

  • 1205 Vascular Calcification


  • Wu, Hongwei, The First Affiliated Hospital of Jinan Universtiy, Guangzhou, China
  • Liu, Fanna, The First Affiliated Hospital of Jinan Universtiy, Guangzhou, China

Recent studies shown that vascular calcification was a osteoblast-like process involving multiple factors. Bone sialoprotein, a recently discovered protein, participated in the metabolism of bone-vascular axis and expressed in the medial layer of calcified vessel in uremia patients. The mechanism of vascular calcification that influenced by bone sialoprotein was not clear. This study was to evaluate the potential association of bone sialoprotein with the development of abdominal aortic calcification (AAC)in maintenance hemodialysis (MHD) patients.


Seventy-five patients who were on MHD between May 2016 and Feb 2017 in the dialysis center were enrolled. Serum bone sialoprotein was tested. AAC was measured by abdomen lateral plain. Kauppila score was used to assess the degree of CAC. Referring to CORD segmentation method, patients was divided into three groups: no or mild calcification group, moderate calcification group and severe group. Logistic regression analysis was used to determine the risk factor of AAC in MHD patients. The diagnostic value of serum bone sialoprotein for AAC was assessed using receiver operator characteristic curve (ROC).


AAC(AACs>4) was present in 49.3% (37/75) patients, the median AAC score was 4(0,24). The median of serum bone sialoprotein was 20.12(18.63,24.21)ng/mL. The serum bone sialoprotein levels were significantly elevated in moderate calcification group and severe group compared to no or mild calcification group [22.43(19.58,26.84)ng/L and 21.99(19.87,26.18)vs 19.16(17.3,23.3)g/L, P<0.05]. Multivariate logistic regression analysis showed that serum bone sialoprotein level was independent risk factor for AAC (OR=1.175,95%CI 1.004~1.375, P<0.05). The area under the ROC curve of serum sclerostin for AAC was 0.718 (95%CI 0.604~0.833,P=0.001), sensitivity was 0.711, and specificity was 0.595 for a cutoff value of 21.51 ng/L.


Serum bone sialoprotein level is associated with AAC. Serum bone sialoprotein level may have a diagnostic value for AAC in MHD patients.


  • Private Foundation Support